De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: The M. D. Anderson and Mayo Clinic experience

Constantine S. Tam, Tait D. Shanafelt, William G. Wierda, Lynne V. Abruzzo, Daniel L. Van Dyke, Susan O'Brien, Alessandra Ferrajoli, Susan A. Lerner, Alice Lynn, Neil Elliot Kay, Michael J. Keating

Research output: Contribution to journalArticle

130 Citations (Scopus)

Abstract

To determine the clinical fate of patients with de novo deletion 17p13.1 (17p-) chronic lymphocytic leukemia (CLL), we retrospectively studied the outcome of 99 treatment-naive 17p- CLL patients from the M. D. Anderson Cancer Center (n = 64) and the Mayo Clinic (n = 35). Among 67 asymptomatic patients followed for progression, 53% developed CLL requiring treatment over 3 years. Patients who had not progressed by 18 months subsequently had stable disease, with 3 of 19 patients progressing after follow-up of up to 70 months. Risk factors for progressive disease were Rai stage of 1 or higher and unmutated immunoglobulin variable region heavy chain (IgVH). The overall survival rate was 65% at 3 years. Rai stage 1 or higher, unmutated IgVH, and 17p- in 25% or more of nuclei were adverse factors for survival. The 3-year survival rates of patients with 1 or fewer, 2, and 3 of these factors were 95%, 74%, and 22%, respectively (P < .001). Response rates to therapy with rituximab (n = 6); purine analogues and rituximab (n = 25); and purine analogues, rituximab, and alemtuzumab (n = 16) combinations were 50%, 72%, and 81%, respectively. Patients with 17p-CLL exhibit clinical heterogeneity, with some patients experiencing an indolent course. Survival can be predicted using clinical and biologic characteristics.

Original languageEnglish (US)
Pages (from-to)957-964
Number of pages8
JournalBlood
Volume114
Issue number5
DOIs
StatePublished - 2009

Fingerprint

B-Cell Chronic Lymphocytic Leukemia
Immunoglobulin Variable Region
Survival Rate
Survival
Rituximab
purine
Therapeutics

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Tam, C. S., Shanafelt, T. D., Wierda, W. G., Abruzzo, L. V., Van Dyke, D. L., O'Brien, S., ... Keating, M. J. (2009). De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: The M. D. Anderson and Mayo Clinic experience. Blood, 114(5), 957-964. https://doi.org/10.1182/blood-2009-03-210591

De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity : The M. D. Anderson and Mayo Clinic experience. / Tam, Constantine S.; Shanafelt, Tait D.; Wierda, William G.; Abruzzo, Lynne V.; Van Dyke, Daniel L.; O'Brien, Susan; Ferrajoli, Alessandra; Lerner, Susan A.; Lynn, Alice; Kay, Neil Elliot; Keating, Michael J.

In: Blood, Vol. 114, No. 5, 2009, p. 957-964.

Research output: Contribution to journalArticle

Tam, CS, Shanafelt, TD, Wierda, WG, Abruzzo, LV, Van Dyke, DL, O'Brien, S, Ferrajoli, A, Lerner, SA, Lynn, A, Kay, NE & Keating, MJ 2009, 'De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: The M. D. Anderson and Mayo Clinic experience', Blood, vol. 114, no. 5, pp. 957-964. https://doi.org/10.1182/blood-2009-03-210591
Tam, Constantine S. ; Shanafelt, Tait D. ; Wierda, William G. ; Abruzzo, Lynne V. ; Van Dyke, Daniel L. ; O'Brien, Susan ; Ferrajoli, Alessandra ; Lerner, Susan A. ; Lynn, Alice ; Kay, Neil Elliot ; Keating, Michael J. / De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity : The M. D. Anderson and Mayo Clinic experience. In: Blood. 2009 ; Vol. 114, No. 5. pp. 957-964.
@article{044920d5034d44ea8815d6e1fa67e9ec,
title = "De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: The M. D. Anderson and Mayo Clinic experience",
abstract = "To determine the clinical fate of patients with de novo deletion 17p13.1 (17p-) chronic lymphocytic leukemia (CLL), we retrospectively studied the outcome of 99 treatment-naive 17p- CLL patients from the M. D. Anderson Cancer Center (n = 64) and the Mayo Clinic (n = 35). Among 67 asymptomatic patients followed for progression, 53{\%} developed CLL requiring treatment over 3 years. Patients who had not progressed by 18 months subsequently had stable disease, with 3 of 19 patients progressing after follow-up of up to 70 months. Risk factors for progressive disease were Rai stage of 1 or higher and unmutated immunoglobulin variable region heavy chain (IgVH). The overall survival rate was 65{\%} at 3 years. Rai stage 1 or higher, unmutated IgVH, and 17p- in 25{\%} or more of nuclei were adverse factors for survival. The 3-year survival rates of patients with 1 or fewer, 2, and 3 of these factors were 95{\%}, 74{\%}, and 22{\%}, respectively (P < .001). Response rates to therapy with rituximab (n = 6); purine analogues and rituximab (n = 25); and purine analogues, rituximab, and alemtuzumab (n = 16) combinations were 50{\%}, 72{\%}, and 81{\%}, respectively. Patients with 17p-CLL exhibit clinical heterogeneity, with some patients experiencing an indolent course. Survival can be predicted using clinical and biologic characteristics.",
author = "Tam, {Constantine S.} and Shanafelt, {Tait D.} and Wierda, {William G.} and Abruzzo, {Lynne V.} and {Van Dyke}, {Daniel L.} and Susan O'Brien and Alessandra Ferrajoli and Lerner, {Susan A.} and Alice Lynn and Kay, {Neil Elliot} and Keating, {Michael J.}",
year = "2009",
doi = "10.1182/blood-2009-03-210591",
language = "English (US)",
volume = "114",
pages = "957--964",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "5",

}

TY - JOUR

T1 - De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity

T2 - The M. D. Anderson and Mayo Clinic experience

AU - Tam, Constantine S.

AU - Shanafelt, Tait D.

AU - Wierda, William G.

AU - Abruzzo, Lynne V.

AU - Van Dyke, Daniel L.

AU - O'Brien, Susan

AU - Ferrajoli, Alessandra

AU - Lerner, Susan A.

AU - Lynn, Alice

AU - Kay, Neil Elliot

AU - Keating, Michael J.

PY - 2009

Y1 - 2009

N2 - To determine the clinical fate of patients with de novo deletion 17p13.1 (17p-) chronic lymphocytic leukemia (CLL), we retrospectively studied the outcome of 99 treatment-naive 17p- CLL patients from the M. D. Anderson Cancer Center (n = 64) and the Mayo Clinic (n = 35). Among 67 asymptomatic patients followed for progression, 53% developed CLL requiring treatment over 3 years. Patients who had not progressed by 18 months subsequently had stable disease, with 3 of 19 patients progressing after follow-up of up to 70 months. Risk factors for progressive disease were Rai stage of 1 or higher and unmutated immunoglobulin variable region heavy chain (IgVH). The overall survival rate was 65% at 3 years. Rai stage 1 or higher, unmutated IgVH, and 17p- in 25% or more of nuclei were adverse factors for survival. The 3-year survival rates of patients with 1 or fewer, 2, and 3 of these factors were 95%, 74%, and 22%, respectively (P < .001). Response rates to therapy with rituximab (n = 6); purine analogues and rituximab (n = 25); and purine analogues, rituximab, and alemtuzumab (n = 16) combinations were 50%, 72%, and 81%, respectively. Patients with 17p-CLL exhibit clinical heterogeneity, with some patients experiencing an indolent course. Survival can be predicted using clinical and biologic characteristics.

AB - To determine the clinical fate of patients with de novo deletion 17p13.1 (17p-) chronic lymphocytic leukemia (CLL), we retrospectively studied the outcome of 99 treatment-naive 17p- CLL patients from the M. D. Anderson Cancer Center (n = 64) and the Mayo Clinic (n = 35). Among 67 asymptomatic patients followed for progression, 53% developed CLL requiring treatment over 3 years. Patients who had not progressed by 18 months subsequently had stable disease, with 3 of 19 patients progressing after follow-up of up to 70 months. Risk factors for progressive disease were Rai stage of 1 or higher and unmutated immunoglobulin variable region heavy chain (IgVH). The overall survival rate was 65% at 3 years. Rai stage 1 or higher, unmutated IgVH, and 17p- in 25% or more of nuclei were adverse factors for survival. The 3-year survival rates of patients with 1 or fewer, 2, and 3 of these factors were 95%, 74%, and 22%, respectively (P < .001). Response rates to therapy with rituximab (n = 6); purine analogues and rituximab (n = 25); and purine analogues, rituximab, and alemtuzumab (n = 16) combinations were 50%, 72%, and 81%, respectively. Patients with 17p-CLL exhibit clinical heterogeneity, with some patients experiencing an indolent course. Survival can be predicted using clinical and biologic characteristics.

UR - http://www.scopus.com/inward/record.url?scp=70349231440&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349231440&partnerID=8YFLogxK

U2 - 10.1182/blood-2009-03-210591

DO - 10.1182/blood-2009-03-210591

M3 - Article

C2 - 19414856

AN - SCOPUS:70349231440

VL - 114

SP - 957

EP - 964

JO - Blood

JF - Blood

SN - 0006-4971

IS - 5

ER -